Contribution of nucleophosmin overexpression to multidrug resistance in breast carcinoma. (2nd January 2018)

• Record Type: Journal Article
• Authors: Chen, Siying; Meng, Ti; Zheng, Xiaowei; Cai, Jiangxia; Zhang, Weipeng; You, Haisheng; Xing, Jianfeng; Dong, Yalin
• Is Part Of: Journal of drug targeting. Volume 26:Number 1(2018)
• Page Start: 27
• Page End: 35
• Publication Date: 2018-01-02
• Subjects: Breast cancer -- MDR -- methotrexate -- NPM -- resistance mechanism; Drug delivery systems -- Periodicals; Drug Delivery Systems; Vehicles; Drug Administration Routes; Drug Evaluation; 615.7
• DOI: 10.1080/1061186X.2017.1332066
• Languages: English
• ISSNs: 1061-186X

Abstract

Abstract: Multidrug resistance (MDR) is a serious obstacle in breast cancer patients which limits chemotherapeutic drugs application. Our previous study confirmed that overexpression of nucleophosmin (NPM) was closely related to MDR in methotrexate-resistant breast cancer cells (MCF-7/MTX), and NPM could be a potential therapeutic target for chemoresistance. In this work, we aim to investigate NPM-mediated resistance mechanism in breast carcinoma. The NPM level was strongly positive in breast carcinoma tissues compared with adjacent normal samples, which was associated with lymph node metastasis. We found abnormal expression of NPM activated PI3K/Akt pathway and affected downstream apoptosis factors. Then, NPM level was attenuated by RNA interfering technology, the sensitivity of MCF-7/MTX cells to methotrexate was obviously increased, factor level of mitochondria apoptosis pathway was significantly augmented, and Akt phosphorylation was inhibited. Furthermore, examination of Akt and NPM level demonstrated that Akt inhibitor MK-2206 sensitised resistant cells to methotrexate and induced MCF-7/MTX cell apoptosis by PI3K/Akt pathway and mitochondria apoptosis pathway. These suggested NPM-induced resistance and anti-apoptosis were required for Akt activity. NPM has a crucial function in MDR of breast cancer through influencing Akt activity and resistant cell apoptosis, and it could be expected to become a therapeutic target for chemoresistance in breast cancer.